Global pharmaceutical company Novo Nordisk A/S (CPH:NOVOB) said on Thursday that the European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents (aged 12 years or over) and adults with haemophilia A. This authorisation covers all 28 EU member states.
Esperoct, the brand name for turoctocog alfa pegol, N8-GP, is indicated for prophylaxis and on-demand treatment of bleeding, as well as for surgical procedures in adolescents and adults with haemophilia A (congenital factor VIII deficiency).
According to the company, the efficacy and safety evaluation was based on the results from the largest pre-registration clinical programme conducted in haemophilia A, with inclusion of 270 previously treated people (PTPs) with severe haemophilia A and more than five years of clinical exposure. This marketing authorisation follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), provided 26 April 2019.
Novo Nordisk expects to launch Esperoct in the first European countries during the second half of 2019.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT